| NCT04460300 |
Effects of Aromatherapy in Hypertensive Individuals |
https://ClinicalTrials.gov/show/NCT04460300 |
Recruiting |
Abant Izzet Baysal University |
2020-08-03 |
| NCT04459741 |
HIV, Immune Activation and Salt Sensitive Hypertension |
https://ClinicalTrials.gov/show/NCT04459741 |
Completed |
Mulungushi University |
2019-12-31 |
| NCT03503773 |
The TARGET BP OFF-MED Trial |
https://ClinicalTrials.gov/show/NCT03503773 |
Recruiting |
Ablative Solutions, Inc. |
2020-09-30 |
| NCT03338426 |
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia |
https://ClinicalTrials.gov/show/NCT03338426 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2019-04-22 |
| NCT03246555 |
Fimasartan in the Senior Subjects |
https://ClinicalTrials.gov/show/NCT03246555 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2019-08-19 |
| NCT03206944 |
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects |
https://ClinicalTrials.gov/show/NCT03206944 |
Completed |
Poznan University of Medical Sciences |
2017-01-01 |
| NCT03186742 |
Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy |
https://ClinicalTrials.gov/show/NCT03186742 |
Completed |
Poznan University of Medical Sciences |
2017-01-01 |
| NCT03179163 |
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans |
https://ClinicalTrials.gov/show/NCT03179163 |
Recruiting |
Penn State University |
2020-08-31 |
| NCT03156842 |
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia |
https://ClinicalTrials.gov/show/NCT03156842 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2018-12-07 |
| NCT03105687 |
Effectiveness of SMS Reminders of Blood Pressure-lowering Drugs Intake |
https://ClinicalTrials.gov/show/NCT03105687 |
Completed |
Comenius University |
2018-01-10 |
| NCT03015311 |
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients |
https://ClinicalTrials.gov/show/NCT03015311 |
Active, not recruiting |
Chinese Academy of Medical Sciences, Fuwai Hospital |
2021-12-31 |
| NCT02996916 |
Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue |
https://ClinicalTrials.gov/show/NCT02996916 |
Recruiting |
Kurume University |
2018-12-31 |
| NCT02944734 |
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02944734 |
Completed |
Shin Poong Pharmaceutical Co. Ltd. |
2015-12-31 |
| NCT02848170 |
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02848170 |
Completed |
Daiichi Sankyo, Inc. |
2017-04-30 |
| NCT02839382 |
The Northwest Coalition for Primary Care Practice Support |
https://ClinicalTrials.gov/show/NCT02839382 |
Completed |
Kaiser Permanente |
2018-05-01 |
| NCT02822222 |
Safety Study of RMJH-111b to Treat Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02822222 |
Completed |
RMJ Holdings, LLC |
2016-07-31 |
| NCT02738632 |
Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients |
https://ClinicalTrials.gov/show/NCT02738632 |
Completed |
IlDong Pharmaceutical Co Ltd |
2016-08-31 |
| NCT02722265 |
Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02722265 |
Completed |
Daiichi Sankyo, Inc. |
2017-07-08 |
| NCT02687178 |
Canrenone as Add-on in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02687178 |
Completed |
University of Pavia |
2015-10-31 |
| NCT02641821 |
Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension |
https://ClinicalTrials.gov/show/NCT02641821 |
Recruiting |
Peking University First Hospital |
2019-12-31 |
| NCT02612298 |
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate |
https://ClinicalTrials.gov/show/NCT02612298 |
Completed |
Sumitomo Pharmaceutical (Suzhou) Co., Ltd. |
2018-09-13 |
| NCT02603809 |
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02603809 |
Completed |
Idorsia Pharmaceuticals Ltd. |
2017-02-28 |
| NCT02031861 |
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02031861 |
Completed |
Shanghai Shyndec Pharmaceutical Co., Ltd. |
2014-07-31 |
| NCT02517866 |
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia |
https://ClinicalTrials.gov/show/NCT02517866 |
Completed |
Takeda |
2016-11-15 |
| NCT02480764 |
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension |
https://ClinicalTrials.gov/show/NCT02480764 |
Completed |
Takeda |
2017-09-22 |
| NCT02466490 |
Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02466490 |
Completed |
Stendhal Americas, S.A. |
2014-02-28 |
| NCT02433119 |
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy |
https://ClinicalTrials.gov/show/NCT02433119 |
Completed |
Dong-A ST Co., Ltd. |
2016-09-08 |
| NCT02419235 |
The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension |
https://ClinicalTrials.gov/show/NCT02419235 |
Completed |
University of Johannesburg |
2015-03-31 |
| NCT02412761 |
Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02412761 |
Completed |
The University of Texas Health Science Center, Houston |
2016-07-31 |
| NCT02345044 |
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects |
https://ClinicalTrials.gov/show/NCT02345044 |
Completed |
Daiichi Sankyo, Inc. |
2015-08-31 |
| NCT02322450 |
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02322450 |
Completed |
Quantum Genomics SA |
2016-04-30 |
| NCT02277691 |
A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02277691 |
Completed |
Takeda |
2016-04-25 |
| NCT02269176 |
Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension |
https://ClinicalTrials.gov/show/NCT02269176 |
Completed |
Boehringer Ingelheim |
2001-01-31 |
| NCT02245230 |
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02245230 |
Recruiting |
Vanderbilt University Medical Center |
2021-12-31 |
| NCT02242370 |
Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02242370 |
Completed |
Boehringer Ingelheim |
2000-11-30 |
| NCT02211352 |
Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02211352 |
Completed |
Daegu Catholic University Medical Center |
2013-12-31 |
| NCT02206659 |
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02206659 |
Completed |
Boehringer Ingelheim |
2001-02-28 |
| NCT02200926 |
Non-pharmacological Treatment for Essential Isolated Systolic Hypertension in Elderly |
https://ClinicalTrials.gov/show/NCT02200926 |
Completed |
Khon Kaen University |
2015-11-30 |
| NCT02194465 |
A Study of LY2623091 in Participants With High Blood Pressure |
https://ClinicalTrials.gov/show/NCT02194465 |
Completed |
Eli Lilly and Company |
2015-03-31 |
| NCT02184858 |
Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension |
https://ClinicalTrials.gov/show/NCT02184858 |
Completed |
University Ghent |
2017-05-08 |
| NCT02183701 |
Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02183701 |
Completed |
Boehringer Ingelheim |
1998-12-31 |
| NCT02177448 |
BIBR 277 Capsule in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02177448 |
Completed |
Boehringer Ingelheim |
1999-09-30 |
| NCT02166814 |
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia |
https://ClinicalTrials.gov/show/NCT02166814 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2015-09-30 |
| NCT02152306 |
Fimasartan/Amlodipine Combination Phase III |
https://ClinicalTrials.gov/show/NCT02152306 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2015-03-31 |
| NCT02079805 |
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R |
https://ClinicalTrials.gov/show/NCT02079805 |
Completed |
Takeda |
2016-04-30 |
| NCT02072330 |
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. |
https://ClinicalTrials.gov/show/NCT02072330 |
Completed |
Takeda |
2013-12-31 |
| NCT02062645 |
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients |
https://ClinicalTrials.gov/show/NCT02062645 |
Completed |
Novartis |
2015-09-30 |
| NCT02058446 |
PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension |
https://ClinicalTrials.gov/show/NCT02058446 |
Completed |
TSH Biopharm Corporation Limited |
2014-03-31 |
| NCT01307046 |
MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) |
https://ClinicalTrials.gov/show/NCT01307046 |
Completed |
Merck Sharp & Dohme Corp. |
2012-02-07 |
| NCT01307033 |
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) |
https://ClinicalTrials.gov/show/NCT01307033 |
Completed |
Merck Sharp & Dohme Corp. |
2012-12-04 |
| NCT01303783 |
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01303783 |
Completed |
Bayer |
2012-05-31 |
| NCT01302691 |
MK-0954E Study in Participants With Hypertension (MK-0954E-357) |
https://ClinicalTrials.gov/show/NCT01302691 |
Completed |
Merck Sharp & Dohme Corp. |
2012-04-01 |
| NCT01299376 |
MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356) |
https://ClinicalTrials.gov/show/NCT01299376 |
Completed |
Merck Sharp & Dohme Corp. |
2011-11-16 |
| NCT01294215 |
High Dose BAYA1040_Nifedipine: a Long Term Combination Study |
https://ClinicalTrials.gov/show/NCT01294215 |
Completed |
Bayer |
2011-11-30 |
| NCT01289899 |
Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT01289899 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2004-02-29 |
| NCT01289886 |
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT01289886 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2003-11-30 |
| NCT01289132 |
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01289132 |
Completed |
Takeda |
2008-07-31 |
| NCT01287260 |
High Dose BAYA1040_Nifedipine: a Dose-comparative Study |
https://ClinicalTrials.gov/show/NCT01287260 |
Completed |
Bayer |
2011-08-31 |
| NCT01904695 |
Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study |
https://ClinicalTrials.gov/show/NCT01904695 |
Completed |
China Academy of Chinese Medical Sciences |
2015-10-31 |
| NCT01900184 |
Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects |
https://ClinicalTrials.gov/show/NCT01900184 |
Completed |
Quantum Genomics SA |
2013-03-31 |
| NCT01900171 |
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo |
https://ClinicalTrials.gov/show/NCT01900171 |
Completed |
Quantum Genomics SA |
2012-05-31 |
| NCT01878201 |
A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01878201 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2014-02-28 |
| NCT01873885 |
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomeraâ„¢ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01873885 |
Completed |
PhaseBio Pharmaceuticals Inc. |
2014-03-31 |
| NCT01842256 |
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin. |
https://ClinicalTrials.gov/show/NCT01842256 |
Completed |
Chong Kun Dang Pharmaceutical |
2013-05-31 |
| NCT01842230 |
Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine |
https://ClinicalTrials.gov/show/NCT01842230 |
Completed |
Chong Kun Dang Pharmaceutical |
2013-05-31 |
| NCT01838850 |
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy |
https://ClinicalTrials.gov/show/NCT01838850 |
Completed |
Daiichi Sankyo, Inc. |
2014-08-31 |
| NCT01788358 |
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01788358 |
Completed |
Bayer |
2014-05-01 |
| NCT01785472 |
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01785472 |
Completed |
Novartis |
2014-08-31 |
| NCT01762436 |
Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01762436 |
Completed |
Ruijin Hospital |
2012-02-29 |
| NCT01756430 |
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01756430 |
Completed |
Chong Kun Dang Pharmaceutical |
2013-09-30 |
| NCT01701726 |
Effect of Acupuncture on Patients With Mild Hypertension |
https://ClinicalTrials.gov/show/NCT01701726 |
Completed |
Chengdu University of Traditional Chinese Medicine |
2016-02-29 |
| NCT01679652 |
The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01679652 |
Completed |
Regional Hospital Holstebro |
2013-09-30 |
| NCT01672476 |
A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01672476 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2013-03-31 |
| NCT01667614 |
Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure |
https://ClinicalTrials.gov/show/NCT01667614 |
Completed |
Tehran University of Medical Sciences |
2012-03-31 |
| NCT01665534 |
Inflammatory Response to Salt in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01665534 |
Completed |
Fondazione C.N.R./Regione Toscana “G. Monasterio”, Pisa, Italy |
2011-03-31 |
| NCT01663233 |
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine |
https://ClinicalTrials.gov/show/NCT01663233 |
Completed |
Novartis |
2013-05-31 |
| NCT01631370 |
The Effects of Renal Denervation on Insulin Sensitivity |
https://ClinicalTrials.gov/show/NCT01631370 |
Completed |
University of Aarhus |
2015-03-30 |
| NCT01631227 |
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01631227 |
Completed |
Abbott |
2013-04-30 |
| NCT01615198 |
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01615198 |
Completed |
Novartis |
2013-07-31 |
| NCT01599104 |
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01599104 |
Completed |
Novartis |
2013-04-30 |
| NCT01566188 |
Vascular Impact of Omega-3 in Metabolic Syndrome |
https://ClinicalTrials.gov/show/NCT01566188 |
Completed |
University Hospital, Rouen |
2014-01-31 |
| NCT01556997 |
Perindopril Amlodipine for the Treatment of Hypertension |
https://ClinicalTrials.gov/show/NCT01556997 |
Completed |
Symplmed Pharmaceuticals LLC |
2013-02-28 |
| NCT01541943 |
Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia |
https://ClinicalTrials.gov/show/NCT01541943 |
Completed |
HanAll BioPharma Co., Ltd. |
2014-11-30 |
| NCT01523067 |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01523067 |
Completed |
PhaseBio Pharmaceuticals Inc. |
2012-12-31 |
| NCT01518855 |
Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01518855 |
Completed |
Bayer |
2005-04-30 |
| NCT01459900 |
Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial |
https://ClinicalTrials.gov/show/NCT01459900 |
Completed |
Aarhus University Hospital Skejby |
2015-02-28 |
| NCT01456169 |
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone |
https://ClinicalTrials.gov/show/NCT01456169 |
Completed |
Takeda |
2012-12-31 |
| NCT01442116 |
Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01442116 |
Completed |
Mustafa Kemal University |
2009-12-31 |
| NCT01417221 |
Renal Sympathetic Modification in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01417221 |
Recruiting |
The Second Affiliated Hospital of Chongqing Medical University |
2019-12-31 |
| NCT01355367 |
High Dose BAYA1040 CR: a Long Term Extension Study |
https://ClinicalTrials.gov/show/NCT01355367 |
Completed |
Bayer |
2011-09-30 |
| NCT01350609 |
Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed |
https://ClinicalTrials.gov/show/NCT01350609 |
Completed |
Bayer |
2011-08-31 |
| NCT01342614 |
The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension |
https://ClinicalTrials.gov/show/NCT01342614 |
Completed |
China-Japan Friendship Hospital |
2009-08-31 |
| NCT04151537 |
Personal Activity Intelligence in the Treatment of High Blood Pressure |
https://ClinicalTrials.gov/show/NCT04151537 |
Recruiting |
Norwegian University of Science and Technology |
2020-09-30 |
| NCT04119999 |
A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling |
https://ClinicalTrials.gov/show/NCT04119999 |
Recruiting |
National University, Singapore |
2023-08-31 |
| NCT04103411 |
Effect of High-Intensity Interval Training Compared to Hydrochlorothiazide on Ambulatory Blood Pressure |
https://ClinicalTrials.gov/show/NCT04103411 |
Recruiting |
Montreal Heart Institute |
2021-06-01 |
| NCT03991442 |
BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination |
https://ClinicalTrials.gov/show/NCT03991442 |
Recruiting |
Boryung Pharmaceutical Co., Ltd |
2021-09-01 |
| NCT03928158 |
LCZ696 in Advanced LV Hypertrophy and HFpEF |
https://ClinicalTrials.gov/show/NCT03928158 |
Recruiting |
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
2020-11-30 |
| NCT03928145 |
Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension. |
https://ClinicalTrials.gov/show/NCT03928145 |
Recruiting |
Hospital de Clinicas de Porto Alegre |
2021-07-31 |
| NCT03924115 |
Evaluation of a Transmedial Psychoeducational Program to Improve Pharmacological Adherence |
https://ClinicalTrials.gov/show/NCT03924115 |
Completed |
Universidad de Concepcion |
2018-12-31 |
| NCT03908710 |
The Accumbo Home Blood Pressure Trial |
https://ClinicalTrials.gov/show/NCT03908710 |
Completed |
Accumbo AB |
2018-10-30 |
| NCT03901183 |
Plant-based Nutrition for Patients With Cardiovascular Risk Factors |
https://ClinicalTrials.gov/show/NCT03901183 |
Recruiting |
Charite University, Berlin, Germany |
2020-07-31 |
| NCT03897868 |
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT03897868 |
Recruiting |
Hanmi Pharmaceutical Company Limited |
2019-11-30 |
| NCT03858595 |
Optimizing Gestational Weight Gain, Birth Weight and Other Perinatal Outcomes Among Pregnant Women at Risk of Hypertension in Pregnancy |
https://ClinicalTrials.gov/show/NCT03858595 |
Recruiting |
International Centre for Diarrhoeal Disease Research, Bangladesh |
2020-10-31 |
| NCT03857490 |
Heat Therapy in Older Hypertensive Women |
https://ClinicalTrials.gov/show/NCT03857490 |
Recruiting |
University of Texas Southwestern Medical Center |
2023-09-30 |
| NCT03803306 |
Vedic Medical Astrology in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT03803306 |
Completed |
NMP Medical Research Institute |
2018-12-15 |
| NCT03778489 |
Impact of Aerobic Exercise Training on Sympathetic Vasoconstriction and Vascular Function in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT03778489 |
Recruiting |
University of Copenhagen |
2020-01-01 |
| NCT03756103 |
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients |
https://ClinicalTrials.gov/show/NCT03756103 |
Recruiting |
Shanghai Pharmaceuticals Holding Co., Ltd |
2020-06-30 |
| NCT03722199 |
Effects of Flavanoids in Essential Hypertension, Type 2 Diabetes and Healthy Persons |
https://ClinicalTrials.gov/show/NCT03722199 |
Active, not recruiting |
University Ghent |
2020-06-20 |
| NCT03566654 |
Clinical Trial on Remote Ischemic Conditioning and Hypertension（HOPE） |
https://ClinicalTrials.gov/show/NCT03566654 |
Recruiting |
Capital Medical University |
2019-12-31 |
| NCT03514641 |
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension |
https://ClinicalTrials.gov/show/NCT03514641 |
Completed |
Theracos |
2018-11-30 |
| NCT03511313 |
Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension |
https://ClinicalTrials.gov/show/NCT03511313 |
Recruiting |
Synaptic Medical Limited |
2020-06-30 |
| NCT03492892 |
Use of Metabolomics to Differentiate the Antihypertensive Effect of Acupuncture From Sham Acupuncture in Hypertensives |
https://ClinicalTrials.gov/show/NCT03492892 |
Completed |
The University of Hong Kong |
2016-08-19 |
| NCT03480217 |
Implementing Hypertension Screening Guidelines in Primary Care |
https://ClinicalTrials.gov/show/NCT03480217 |
Recruiting |
Columbia University |
2019-04-02 |
| NCT03479697 |
HIRREM for Stage 1 Primary Hypertension |
https://ClinicalTrials.gov/show/NCT03479697 |
Recruiting |
Wake Forest University Health Sciences |
2020-07-31 |
| NCT01264692 |
Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01264692 |
Completed |
Idorsia Pharmaceuticals Ltd. |
2012-01-31 |
| NCT01258673 |
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy |
https://ClinicalTrials.gov/show/NCT01258673 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2011-12-31 |
| NCT01256411 |
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01256411 |
Completed |
Novartis |
2012-04-30 |
| NCT01251146 |
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System’s Activity in Subjects With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01251146 |
Completed |
Merck KGaA, Darmstadt, Germany |
2012-02-29 |
| NCT01241487 |
A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy |
https://ClinicalTrials.gov/show/NCT01241487 |
Completed |
Novartis |
2011-01-31 |
| NCT01237873 |
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01237873 |
Completed |
Novartis |
2012-02-29 |
| NCT01237223 |
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01237223 |
Completed |
Novartis |
2011-05-31 |
| NCT01227603 |
Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions |
https://ClinicalTrials.gov/show/NCT01227603 |
Completed |
Bayer |
2011-03-31 |
| NCT01198249 |
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension |
https://ClinicalTrials.gov/show/NCT01198249 |
Completed |
Yonsei University |
2011-02-28 |
| NCT01195805 |
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables |
https://ClinicalTrials.gov/show/NCT01195805 |
Completed |
Regional Hospital Holstebro |
2015-08-31 |
| NCT01193101 |
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01193101 |
Completed |
Novartis |
2011-04-30 |
| NCT01180413 |
Intensive Vasodilator Therapy in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01180413 |
Completed |
Aarhus University Hospital |
2012-04-30 |
| NCT01146938 |
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01146938 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2011-02-28 |
| NCT01135212 |
The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01135212 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2011-04-30 |
| NCT01131546 |
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01131546 |
Completed |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2011-03-31 |
| NCT01126684 |
Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion |
https://ClinicalTrials.gov/show/NCT01126684 |
Completed |
Aristotle University Of Thessaloniki |
2009-12-31 |
| NCT01122251 |
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01122251 |
Completed |
LG Life Sciences |
2010-05-31 |
| NCT01120990 |
Hybrid Blood Pressure Monitor Validation |
https://ClinicalTrials.gov/show/NCT01120990 |
Completed |
University of Athens |
2010-06-30 |
| NCT01113047 |
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine |
https://ClinicalTrials.gov/show/NCT01113047 |
Completed |
Novartis |
2010-10-31 |
| NCT01093807 |
Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01093807 |
Completed |
Recordati Industria Chimica e Farmaceutica S.p.A. |
2011-03-31 |
| NCT01042392 |
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients |
https://ClinicalTrials.gov/show/NCT01042392 |
Completed |
Novartis |
2011-01-31 |
| NCT01033071 |
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension. |
https://ClinicalTrials.gov/show/NCT01033071 |
Completed |
Takeda |
2010-10-31 |
| NCT01013155 |
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions |
https://ClinicalTrials.gov/show/NCT01013155 |
Completed |
West-Ward Pharmaceutical |
2007-05-31 |
| NCT01012687 |
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions |
https://ClinicalTrials.gov/show/NCT01012687 |
Completed |
West-Ward Pharmaceutical |
2007-05-31 |
| NCT01001572 |
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01001572 |
Completed |
Novartis |
2010-05-31 |
| NCT00996281 |
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00996281 |
Completed |
Takeda |
2011-11-30 |
| NCT00991783 |
A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT00991783 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-11-30 |
| NCT00991705 |
A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT00991705 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-09-30 |
| NCT00942344 |
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00942344 |
Completed |
Hanmi Pharmaceutical Company Limited |
2007-12-31 |
| NCT00940680 |
Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00940680 |
Completed |
Hanmi Pharmaceutical Company Limited |
2008-11-30 |
| NCT00940667 |
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00940667 |
Completed |
Hanmi Pharmaceutical Company Limited |
2008-12-31 |
| NCT00938262 |
A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT00938262 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-06-30 |
| NCT00938197 |
A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT00938197 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-08-31 |
| NCT00938132 |
A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT00938132 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-09-30 |
| NCT00937651 |
Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K) |
https://ClinicalTrials.gov/show/NCT00937651 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2006-06-30 |
| NCT00937534 |
Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers |
https://ClinicalTrials.gov/show/NCT00937534 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-08-31 |
| NCT00923611 |
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients |
https://ClinicalTrials.gov/show/NCT00923611 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2008-06-30 |
| NCT00923091 |
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension |
https://ClinicalTrials.gov/show/NCT00923091 |
Completed |
Daiichi Sankyo, Inc. |
2011-01-31 |
| NCT00922441 |
A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00922441 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-08-31 |
| NCT00923533 |
A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT00923533 |
Completed |
Boryung Pharmaceutical Co., Ltd |
2009-05-31 |
| NCT00902538 |
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension |
https://ClinicalTrials.gov/show/NCT00902538 |
Completed |
Daiichi Sankyo, Inc. |
2010-09-30 |
| NCT00890591 |
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00890591 |
Completed |
Daiichi Sankyo, Inc. |
2007-06-30 |
| NCT00872586 |
Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00872586 |
Completed |
Daiichi Sankyo, Inc. |
2007-07-31 |
| NCT00865501 |
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease |
https://ClinicalTrials.gov/show/NCT00865501 |
Completed |
University of Erlangen-Nürnberg Medical School |
2009-12-31 |
| NCT00858702 |
Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension |
https://ClinicalTrials.gov/show/NCT00858702 |
Completed |
Daiichi Sankyo, Inc. |
2005-07-31 |
| NCT00857285 |
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension |
https://ClinicalTrials.gov/show/NCT00857285 |
Completed |
Daiichi Sankyo, Inc. |
2003-08-31 |
| NCT00856271 |
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00856271 |
Completed |
Daiichi Sankyo, Inc. |
2005-02-28 |
| NCT00846365 |
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension |
https://ClinicalTrials.gov/show/NCT00846365 |
Completed |
Takeda |
2010-06-30 |
| NCT03276598 |
A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT03276598 |
Completed |
Helsinki University Central Hospital |
2004-04-01 |
| NCT01527760 |
Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT01527760 |
Completed |
Fr Muller Homoeopathic Medical College |
2011-08-31 |
| NCT03258489 |
Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients |
https://ClinicalTrials.gov/show/NCT03258489 |
Completed |
Universidade Federal de Santa Maria |
2019-12-09 |
| NCT02890173 |
Study of CS-3150 in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT02890173 |
Completed |
Daiichi Sankyo, Inc. |
2017-07-11 |
| NCT02579356 |
To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT02579356 |
Completed |
Samil Pharmaceutical Co., Ltd. |
2014-08-31 |
| NCT00779181 |
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00779181 |
Completed |
Addrenex Pharmaceuticals, Inc. |
2008-12-31 |
| NCT00765947 |
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension |
https://ClinicalTrials.gov/show/NCT00765947 |
Completed |
Novartis |
2009-08-31 |
| NCT00760214 |
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00760214 |
Completed |
Takeda |
2009-04-30 |
| NCT00759551 |
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00759551 |
Completed |
Takeda |
2005-06-30 |
| NCT00758524 |
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00758524 |
Completed |
Novartis |
2009-07-31 |
| NCT00751751 |
Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly |
https://ClinicalTrials.gov/show/NCT00751751 |
Completed |
Daiichi Sankyo, Inc. |
2005-04-30 |
| NCT00739973 |
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00739973 |
Completed |
Novartis |
2009-05-31 |
| NCT00710372 |
Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00710372 |
Completed |
Cytos Biotechnology AG |
2009-07-31 |
| NCT00709930 |
Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00709930 |
Completed |
Kyoto University |
2008-08-31 |
| NCT00706134 |
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study |
https://ClinicalTrials.gov/show/NCT00706134 |
Completed |
Novartis |
2009-04-30 |
| NCT00701649 |
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00701649 |
Completed |
Cytos Biotechnology AG |
2009-03-31 |
| NCT00699192 |
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00699192 |
Completed |
Novartis |
2009-05-31 |
| NCT00696436 |
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension. |
https://ClinicalTrials.gov/show/NCT00696436 |
Completed |
Takeda |
2009-08-31 |
| NCT00696384 |
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00696384 |
Completed |
Takeda |
2009-04-30 |
| NCT00696241 |
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00696241 |
Completed |
Takeda |
2008-10-31 |
| NCT00695955 |
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00695955 |
Completed |
Takeda |
2010-05-31 |
| NCT00687973 |
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg |
https://ClinicalTrials.gov/show/NCT00687973 |
Completed |
Novartis |
2009-01-31 |
| NCT00667719 |
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00667719 |
Completed |
Novartis |
2009-10-31 |
| NCT00662896 |
To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00662896 |
Completed |
NicOx |
2008-09-30 |
| NCT00654875 |
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. |
https://ClinicalTrials.gov/show/NCT00654875 |
Completed |
Novartis |
2008-11-30 |
| NCT00631917 |
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00631917 |
Completed |
Novartis |
2009-09-30 |
| NCT00624065 |
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure |
https://ClinicalTrials.gov/show/NCT00624065 |
Completed |
GlaxoSmithKline |
2008-08-31 |
| NCT00591773 |
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00591773 |
Completed |
Takeda |
2009-03-31 |
| NCT00591578 |
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00591578 |
Completed |
Takeda |
2009-09-30 |
| NCT00591266 |
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00591266 |
Completed |
Takeda |
2009-03-31 |
| NCT00591253 |
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00591253 |
Completed |
Takeda |
2009-04-30 |
| NCT00553865 |
Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets |
https://ClinicalTrials.gov/show/NCT00553865 |
Completed |
Jeil Pharmaceutical Co., Ltd. |
2008-10-31 |
| NCT00549770 |
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00549770 |
Completed |
Novartis |
2008-07-31 |
| NCT00546754 |
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) |
https://ClinicalTrials.gov/show/NCT00546754 |
Completed |
Merck Sharp & Dohme Corp. |
2009-04-01 |
| NCT00529451 |
Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg |
https://ClinicalTrials.gov/show/NCT00529451 |
Completed |
Novartis |
2008-07-31 |
| NCT00509470 |
Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine |
https://ClinicalTrials.gov/show/NCT00509470 |
Completed |
Tokyo University |
2012-06-30 |
| NCT00500786 |
Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb |
https://ClinicalTrials.gov/show/NCT00500786 |
Completed |
Cytos Biotechnology AG |
2006-09-30 |
| NCT00461903 |
Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00461903 |
Completed |
Montreal Heart Institute |
2015-09-30 |
| NCT00457483 |
Nijmegen Antihypertensive Management Improvement Study |
https://ClinicalTrials.gov/show/NCT00457483 |
Completed |
Radboud University |
2010-12-31 |
| NCT00446524 |
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301) |
https://ClinicalTrials.gov/show/NCT00446524 |
Completed |
Novartis |
2008-10-31 |
| NCT00441350 |
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00441350 |
Completed |
Menarini Group |
2008-05-31 |
| NCT00438945 |
The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00438945 |
Completed |
Regional Hospital Holstebro |
NA |
| NCT00437645 |
Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00437645 |
Completed |
Novartis |
2007-11-30 |
| NCT00430950 |
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00430950 |
Completed |
Daiichi Sankyo, Inc. |
2008-05-31 |
| NCT00430508 |
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00430508 |
Completed |
Daiichi Sankyo, Inc. |
2008-03-31 |
| NCT00425373 |
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00425373 |
Completed |
Novartis |
2008-03-31 |
| NCT00424541 |
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00424541 |
Completed |
Novartis |
NA |
| NCT00415038 |
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00415038 |
Completed |
sigma-tau i.f.r. S.p.A. |
2007-04-30 |
| NCT00408512 |
Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study |
https://ClinicalTrials.gov/show/NCT00408512 |
Completed |
Federico II University |
2009-12-31 |
| NCT00367094 |
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00367094 |
Completed |
Novartis |
NA |
| NCT00355589 |
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00355589 |
Completed |
Pfizer |
2007-03-31 |
| NCT00345150 |
Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls |
https://ClinicalTrials.gov/show/NCT00345150 |
Completed |
Regional Hospital Holstebro |
NA |
| NCT00345124 |
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00345124 |
Completed |
Regional Hospital Holstebro |
2009-05-31 |
| NCT00344110 |
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00344110 |
Completed |
Novartis |
2007-04-30 |
| NCT00343551 |
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension. |
https://ClinicalTrials.gov/show/NCT00343551 |
Completed |
Novartis |
2007-01-31 |
| NCT00338936 |
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) |
https://ClinicalTrials.gov/show/NCT00338936 |
Completed |
Novartis |
2007-09-30 |
| NCT00328965 |
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea |
https://ClinicalTrials.gov/show/NCT00328965 |
Completed |
GlaxoSmithKline |
2006-05-31 |
| NCT00311740 |
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study) |
https://ClinicalTrials.gov/show/NCT00311740 |
Completed |
Novartis |
2006-09-30 |
| NCT00311155 |
Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension |
https://ClinicalTrials.gov/show/NCT00311155 |
Completed |
Daiichi Sankyo, Inc. |
2008-04-30 |
| NCT00295555 |
Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy |
https://ClinicalTrials.gov/show/NCT00295555 |
Completed |
Yokohama City University Medical Center |
NA |
| NCT00288184 |
Uric Acid in Essential Hypertension in Children |
https://ClinicalTrials.gov/show/NCT00288184 |
Completed |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2007-03-31 |
| NCT00257491 |
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00257491 |
Completed |
Boehringer Ingelheim |
2006-08-31 |
| NCT00254475 |
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00254475 |
Completed |
Novartis |
2006-09-30 |
| NCT00246584 |
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US) |
https://ClinicalTrials.gov/show/NCT00246584 |
Completed |
Novartis |
NA |
| NCT00236665 |
A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00236665 |
Completed |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
NA |
| NCT00220233 |
Olmesartan as an add-on to Amlodipine in Hypertension |
https://ClinicalTrials.gov/show/NCT00220233 |
Completed |
Daiichi Sankyo, Inc. |
NA |
| NCT00220220 |
Amlodipine as add-on to Olmesartan in Hypertension |
https://ClinicalTrials.gov/show/NCT00220220 |
Completed |
Daiichi Sankyo, Inc. |
NA |
| NCT00219141 |
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00219141 |
Completed |
Novartis |
2007-11-30 |
| NCT00219037 |
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00219037 |
Completed |
Novartis |
2005-10-31 |
| NCT00219024 |
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension. |
https://ClinicalTrials.gov/show/NCT00219024 |
Completed |
Novartis |
2005-06-30 |
| NCT00185185 |
Olmesartan Medoxomil in Atherosclerosis |
https://ClinicalTrials.gov/show/NCT00185185 |
Completed |
Daiichi Sankyo, Inc. |
NA |
| NCT00185172 |
Olmesartan in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00185172 |
Completed |
Daiichi Sankyo, Inc. |
2005-06-30 |
| NCT00157963 |
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) |
https://ClinicalTrials.gov/show/NCT00157963 |
Completed |
Merck Sharp & Dohme Corp. |
2006-02-08 |
| NCT00153049 |
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00153049 |
Completed |
Boehringer Ingelheim |
2005-06-30 |
| NCT00151827 |
Olmesartan Medoxomil in Hypertension and Renal Impairment |
https://ClinicalTrials.gov/show/NCT00151827 |
Completed |
Daiichi Sankyo, Inc. |
2005-07-31 |
| NCT00139698 |
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00139698 |
Completed |
Pfizer |
NA |
| NCT00138944 |
Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension |
https://ClinicalTrials.gov/show/NCT00138944 |
Completed |
University of Erlangen-Nürnberg Medical School |
2008-05-31 |
| NCT00137124 |
L-Arginine Metabolism in Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00137124 |
Completed |
University of Erlangen-Nürnberg Medical School |
2009-12-31 |
| NCT00131846 |
Diuretics In the Management of Essential Hypertension (DIME) Study |
https://ClinicalTrials.gov/show/NCT00131846 |
Completed |
Kyoto University |
2012-08-31 |
| NCT00130156 |
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension |
https://ClinicalTrials.gov/show/NCT00130156 |
Completed |
Eisai Inc. |
2008-09-30 |
| NCT00102141 |
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women |
https://ClinicalTrials.gov/show/NCT00102141 |
Completed |
Bayer |
NA |
| NCT00092209 |
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302) |
https://ClinicalTrials.gov/show/NCT00092209 |
Completed |
Merck Sharp & Dohme Corp. |
2002-11-30 |
| NCT00819104 |
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components |
https://ClinicalTrials.gov/show/NCT00819104 |
Completed |
AstraZeneca |
NA |
| NCT00818883 |
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension |
https://ClinicalTrials.gov/show/NCT00818883 |
Completed |
Takeda |
2009-11-30 |
| NCT00794885 |
China Stroke Primary Prevention Trial |
https://ClinicalTrials.gov/show/NCT00794885 |
Completed |
Shenzhen Ausa Pharmed Co.,Ltd |
2013-08-31 |
| NCT00741585 |
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment |
https://ClinicalTrials.gov/show/NCT00741585 |
Completed |
University of Vigo |
2018-06-30 |
| NCT00026065 |
Hypertension: Prediction of Biofeedback Success |
https://ClinicalTrials.gov/show/NCT00026065 |
Completed |
National Center for Complementary and Integrative Health (NCCIH) |
NA |